Upending previous research, study finds no evidence of status-quo bias favoring standard care when two or more appropriate alternatives are presented.

Late-breaking results from clinical trials, debates about lifestyle choices and cardiovascular risk, and improving clinical care with generative AI are among the topics being presented by UC San ...

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

The SAM-002 trial is a 24-week, multicentre, randomised, placebo-controlled Phase 3 study designed to assess the safety and efficacy of sublingual minoxidil in men with AGA. Participants were ...

Self-administered hypnosis effectively alleviates hot flashes in menopausal women, enhancing quality of life and providing an ...

Maintaining a healthy blood sugar level can reduce your disease risk and give you more energy. These 15 habits help keep ...

What study showed data for zanubrutinib in previously untreated CLL? Mazyar Shadman, MD, MPH: The SEQUOIA study was a larger ...

The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...

New research reveals that tirzepatide and semaglutide both offer strong, early heart-protective effects. A major new ...

Phase 3 accelerated approval trial of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy ...

FDA Alignment -- BioAtla ( BCAB 4.08%) achieved FDA alignment on phase three trial design, dosing, comparator, and endpoints ...

A cup of coffee a day did not worsen atrial fibrillation (AF) in adults recovering from electrical cardioversion, and it may even lower the likelihood of recurrent arrhythmia, according to new ...